Author:
Moyo Tamara K.,Savona Michael R.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Reference74 articles.
1. Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. doi: 10.1182/blood-2016-03-643544 .
2. Savona MR, et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015;125:1857–65. doi: 10.1182/blood-2014-10-607341 .
3. Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML—dysplastic versus proliferative type. Leuk Res. 1998;22:871–8.
4. Nosslinger T, et al. Dysplastic versus proliferative CMML—a retrospective analysis of 91 patients from a single institution. Leuk Res. 2001;25:741–7.
5. •• Patnaik MM, et al. “Proliferative” versus “dysplastic” chronic myelomonocytic leukemia: molecular and prognostic correlates. Blood. 2016;128:1987. Although simply defined by total leukocyte count, Patnaik et al. demonstrated that specific recurrent molecular mutations segregate MD-CMML and MP-CMML. Whereas SF3B1 mutations were more common in MD-CMML, mutations in ASXL1, JAK2, CBL, and genes of the RAS family are more prevalent in MP-CMML, which hints at differential underlying disease biologies. These identified differences will likely impact treatment in the future, especially as targeted therapies are sought. This work led to the WHO recommendation for distinction between MD-CMML and MP-CMML.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献